体聚乙烯结合 bis-hydrazothiazoles:作为肝癌中癌症终止剂的架构通过亡
Magdi E A Zaki1, Abdulrahman S Alharbi2, Zeinab A Muhammad3
1Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Future medicinal chemistry
|October 25, 2025
概括
研究人员开发了新的聚乙烯结合 bis-hydrazothiazoles 作为潜在的抗癌剂. 替代衍生物显示出显著的细胞毒性和对肝癌细胞的选择性,诱导细胞亡和抑制Pim-1激酶.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症研究 癌症研究
背景情况:
- 新型抗癌药物的开发对于对抗癌症至关重要.
- 双二衍生物代表了一类有前途的异环化合物.
研究的目的:
- 合成和描述两组聚乙烯结合 bis-hydrazothiazole衍生物的区域异构组.
- 评估这些化合物的体外抗癌活性,对抗各种癌症细胞系.
- 研究最强效衍生物的作用机制和潜在的分子标.
主要方法:
- 使用bis-phenacyl化物和bis-thiosemicarbazones作为构建块的bis-hydrazothiazole衍生物的合成.
- 在体外查肝 (HepG-2),肺 (A-549),结直肠 (HCT-116),前列腺 (PC-3) 癌细胞系.
- 使用IC50值和亡试验进行细胞毒性评估.
- 分子对接模拟以评估与潜在目标的结合亲和力,如Pim-1激酶.
主要成果:
- 新型双二醇8a-l和10a-l已成功合成.
- 替代衍生物 (8c,8i,10c,10i) 对HepG-2肝癌细胞表现出显著的细胞毒性和选择性 (IC50值在10.3至23.9微米之间).
- 这些强效化合物诱导了显著的亡 (高达35.68%) 并显示出抑制Pim-1激酶的潜力,这是分子对接研究所支持的.
结论:
- 开发了两种新型的聚乙烯结合 bis-hydrazothiazoles 的区域异构组.
- 合成的双 heterocycles 显示出高选择性和强大的抗癌活性对HepG2肝癌.
- 这些化合物代表了作为抗癌疗法进一步开发的有希望的原型.
更多相关视频
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
The Intrinsic Apoptotic Pathway
8.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K


